Table 7.

Adverse events after 6 months of combined therapy of onabotulinumtoxinA and anti-CGRP mAbs occur in a percentage of patients ranging from 12.1% to 14.2%.

Study Report (Author and Year)	6 Months
Blumenfeld et al., 2021 [47]	14.2% (n = 28/197)
Mechtler et al., 2022 [48]	12.1% (n = 18/148)
Pooled results	13.3% (n = 46/345)